irinotecan liposome II + 5-fluorouracil + leucovorin + oxaliplatin

This combination regimen, often referred to as a modified NALIRIFOX regimen, consists of irinotecan liposome II, 5-fluorouracil (5-FU), leucovorin, and oxaliplatin. It is currently being investigated in a Phase II clinical trial led by Peking Union Medical College Hospital for the perioperative treatment of borderline resectable pancreatic cancer. Irinotecan liposome II is a second-generation liposomal formulation of the topoisomerase I inhibitor irinotecan, developed by CSPC Pharmaceutical Group to enhance drug delivery and reduce systemic toxicity compared to conventional irinotecan. Oxaliplatin is a platinum-based agent that induces DNA damage through the formation of intra- and inter-strand cross-links. 5-fluorouracil is an antimetabolite that inhibits thymidylate synthase, while leucovorin (folinic acid) is administered to stabilize the binding of 5-FU to thymidylate synthase, thereby increasing its cytotoxic efficacy.

Other names

irinotecan liposome II combined with 5-FU/LV and oxaliplatinmNALIRIFOXmodified NALIRIFOX